Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-29T22:50:08.851Z Has data issue: false hasContentIssue false

Psychiatric symptoms in people living with HIV: prevalences, interactions and consequences

Published online by Cambridge University Press:  19 July 2023

E. M. Meeder*
Affiliation:
Psychiatry
M. Blaauw
Affiliation:
Internal Medicine, Radboudumc, Nijmegen
L. E. van Eekeren
Affiliation:
Internal Medicine, Radboudumc, Nijmegen
A. Groenendijk
Affiliation:
Internal Medicine, Radboudumc, Nijmegen
W. A. Vos
Affiliation:
Internal Medicine, Radboudumc, Nijmegen
Q. de Mast
Affiliation:
Internal Medicine, Radboudumc, Nijmegen
W. L. Blok
Affiliation:
Internal Medicine, OLVG, Amsterdam
A. Verbon
Affiliation:
Internal Medicine, Erasmus MC, Rotterdam
M. A. Berrevoets
Affiliation:
Internal Medicine, Elisabeth-Tweesteden Ziekenhuis, Tilburg, Netherlands
J. van Lunzen
Affiliation:
ViiV Healthcare, London, United Kingdom
L. Joosten
Affiliation:
Internal Medicine, Radboudumc, Nijmegen
M. Netea
Affiliation:
Internal Medicine, Radboudumc, Nijmegen
V. Matzaraki
Affiliation:
Internal Medicine, Radboudumc, Nijmegen
A. J. van der Ven
Affiliation:
Internal Medicine, Radboudumc, Nijmegen
A. F. Schellekens
Affiliation:
Psychiatry
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

People living with HIV (PLHIV) experience higher levels of mental health issues compared to the general population. Especially depression, anxiety, impulsivity and substance use occur frequently in PLHIV. This is thought to have important consequences for quality of life, sexual risk behaviour and antiretroviral treatment (ART) adherence. Both in PLHIV as well as in the general population, divergent psychiatric symptoms often co-occur, and influence one another.

Objectives

To assess the interrelatedness of psychiatric symptoms and their potential consequences in PLHIV.

Methods

Data from 1615 outpatient PLHIV using suppressive ART from the 2000HIV study (NCT03994835) were analysed. Participants reported on the severity of substance use (MATE-Q), depression and anxiety (HADS), impulsivity (BIS-11), quality of life (EQ-5D-5L), ART adherence (MASS-8) and sexual risk behaviour. For these variables, prevalence rates and mean scores were calculated. After binarizing the data, an Ising network model was constructed. Using this network, interrelations between psychiatric symptoms were assessed, the centrality of symptoms was estimated and connections with clinical consequences were explored.

Results

In our cohort of PLHIV, the increased prevalence of substance use was most pronounced, as shown by a prevalence rate of 28.7% for smoking, 13.6% for cannabis use, 11.1% for heavy alcohol drinking and 9.2% for ecstasy use in the past month. The network analysis revealed that symptoms of depression and anxiety were most strongly interrelated. The depressive symptom “feeling slowed down” was one of the most central symptoms, and was most strongly connected with quality of life. Substance use was associated with a higher occurrence of sexually transmitted diseases, and this relationship was mediated by a higher number of sexual partners. Notably, ART adherence did not display any connections with depression, anxiety, impulsivity or substance use.

Image:

Conclusions

The high occurrence of substance use and its link with sexual risk behaviour, emphasizes it’s role as a potential target for prevention of HIV transmission. Contrary to general assumption, psychiatric symptoms are not associated with lower levels of ART adherence in our cohort. Treatment of depression in PLHIV might be improved by focussing on the symptom of feeling slowed down, since this symptom was most strongly connected with quality of life.

Disclosure of Interest

E. Meeder Grant / Research support from: ViiV Healthcare, M. Blaauw: None Declared, L. van Eekeren: None Declared, A. Groenendijk: None Declared, W. Vos: None Declared, Q. de Mast: None Declared, W. Blok: None Declared, A. Verbon: None Declared, M. Berrevoets: None Declared, J. van Lunzen Employee of: ViiV Healthcare, L. Joosten: None Declared, M. Netea: None Declared, V. Matzaraki: None Declared, A. van der Ven: None Declared, A. Schellekens: None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.